Please login to the form below

Not currently logged in
Email:
Password:

breast cancer

This page shows the latest breast cancer news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and ... It also gave its blessing to Clovis

Latest news

More from news
Approximately 92 fully matching, plus 654 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... Women could be denied access to a drug for incurable breast cancer, ’tweeted an oncology nurse.

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Breast Cancer Now is followed by almost 40, 000, and its

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    A joint study by the University of Nottingham, UK, and Kaohsiung Medical University, Taiwan, suggests for example that in breast cancer, non-adherence to adjuvant hormonal therapy increases all-cause mortality

More from intelligence
Approximately 1 fully matching, plus 51 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    s cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

  • Ipsen boosts specialty care and R&D leadership teams Ipsen boosts specialty care and R&D leadership teams

    Prior to this, he served as executive director and breast cancer lead for US oncology medical affairs, and held a number of medical affairs oncology positions at Novartis and Bayer.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Agendia appoints chairman of medical advisory board Agendia appoints chairman of medical advisory board

    Dr Hortobagyi brings over 35 years of experience in clinical and translational research of breast cancer and work as a breast medical oncologist to the molecular cancer diagnostics company. ... He currently also serves as a professor and chair Emeritus

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • FALCON trial of fulvestrant for advanced breast cancer

    FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics